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ess: jaejshim@kumc.or.Summary Cigarette smoke may be the main cause of chronic bronchitis. Exposure
of cigarette smoke induces the recruitment of inflammatory cells in the airway
epithelium, and release of the tumor necrosis factor a (TNFa) from airways. Previous
reports have shown that cigarette smoke induces goblet cell metaplasia by
activating an epidermal growth factor receptor (EGFR) cascade, and that this
results in mucin production. Rebamipide (2-(4-chlorobenzoylamino)-3-[2(1H)-quino-
linon-4-yl] propionic acid, OPC-12759) directly inhibits the production of superoxide
(O2
) and inhibits proinflammatory cytokines (such as TNFa and IL-8). In the present
study, we aimed to analyze the inhibitory effects of rebamipide on TNFa and EGFR
activation after cigarette smoke treatment in vitro and in vivo.
NCl-H292 cells and Sprague-Dawley rats were used for in vitro and in vivo studies.
In vitro studies, cigarette smoke solution was found to increase TNFa secretion, and
EGFR-specific tyrosine phosphorylation, and to elevate MUC5AC production. These
effects were inhibited dose-dependently by pretreatment with rebamipide (MUC5AC
protein levels were inhibited from 44% to 17%, Po0:05). In vivo studies, cigarette
smoke was found to cause inflammatory cell recruitment and to increase the
secretion of TNFa in bronchoalveolar lavage (BAL) fluids (from 198778 to
22707158 pg/ml, Po0:01). Moreover, the pretreatment of rats with rebamipide
inhibited goblet cell metaplasia and TNFa secretion, dose-dependently (from
22707158 to 13777112 pg/ml, Po0:05).
In conclusion, the exposure of airway epithelium to cigarette smoke-induced
TNFa production, neutrophil recruitment, activated EGFR, and caused MUC5ACElsevier Ltd. All rights reserved.
orea Research Foundation Grant (KRF-2004-041-E00145).
18 6639; fax: +82 2 865 9670.
kr (J.J. Shim).
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S.Y. Lee et al.504mucin synthesis. Moreover, rebamipide was found to prevent this cigarette smoke-
induced TNFa release, and mucin production.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The hallmarks of chronic bronchitis are cough and
excessive mucus production, and cigarette smoke is
viewed as a major etiologic factor of chronic
bronchitis. Exposure to cigarette smoke has been
reported to induce goblet cell metaplasia and
mucus production, the recruitment of inflammatory
cells, including neutrophils, in the airway epithe-
lium, and the release of tumor necrosis factor a
(TNFa) from airway epithelium.1,2 Mucin MUC5AC is
a major mucin in the airway epithelium.3 Mucin
synthesis in airways has been reported to be
regulated by the epidermal growth factor receptor
(EGFR) system.4–8 Moreover, EGFR is known to be
upregulated by the proinflammatory cytokine TNFa,
which upregulated in hypersecretory airway dis-
eases.5–9 Moreover, stimulation with TNFa induces
EGFR expression in human epithelial cells in vitro
and in rats in vivo, and the activation of EGFR by its
ligands or by oxidative stress results in mucin
production.4,6,7,10 Activated neutrophils release
oxygen-free radicals, which cause mucin synthesis
via EGFR transactivation, and these effects are
blocked by EGFR tyrosine kinase inhibitors and also
by antioxidants. In addition, cigarette smoke
induces goblet cell metaplasia by activating an
EGFR cascade which releases TNFa, resulting in
mucin expression.11
Rebamipide (2-(4-chlorobenzoylamino)-3-[2(1H)-
quinolinon-4-yl] propionic acid, OPC-12759) is a
gastro-protective agent used in the treatment of
gastritis and ulcerative colitis; however, the me-
chanisms of its anti-inflammatory action are not
completely understood.12–14 Nevertheless, rebami-
pide is known to directly inhibit the production of
superoxide (O2
) and to eliminate reactive oxygen
species (ROS) in hydroxyl radical (OH) system.15–18
In addition, rebamipide protects the gastric mucosa
against acute injury caused by various noxious and
ulcerogenic factors. Recently, several reports have
shown that rebamipide works as an anti-inflamma-
tory agent in both acute and chronic inflammation,
and has an inhibitory effect on proinflammatory
cytokines (such as TNFa and IL-8) and on the
activation of neutrophils.19–21
In the present study, we investigated the
inhibitory effects of rebamipide on cigarette
smoke-induced mucin production in airway epithe-
lium, since the compound is known as inhibitor ofproinflammatory cytokines, neutrophil activation,
and oxidative stress.Materials and methods
In vitro studies
Preparation of cigarette smoke solution: Standard
research cigarettes (code 2R4F, produced by the
Tobacco and Health Research Institute, University
of Kentucky) were used. Cigarette smoke solution
was prepared as previously described.11 In brief,
cigarette smoke was withdrawn into a polypropy-
lene syringe (35ml) at a rate of one puff/min and
then bubbled slowly into 20ml of RPMI 1640
medium containing 50mM HEPES buffer. The smoke
solution was then titrated to pH 7.4 and used
immediately after preparation.
Cell culture: NCI-H292 cells, a human pulmonary
mucoepidermoid carcinoma cell line, were grown
in RPMI 1640 medium containing 10% fetal bovine
serum, penicillin (100U/ml), streptomycin (100 mg/
ml), and HEPES (25mM) at 37 1C in a humidified 5%
CO2 water-jacketed incubator. Cells were cultured
in either six-well culture plates or eight-chamber
slides. When confluent, cells were incubated for 1 h
in cigarettes smoke solution. They were then
washed and incubated with fresh medium alone.
Experiments were terminated at 24 h for protein
measurements. As controls, NCI-H292 cells were
incubated with medium alone in an identical
manner. In inhibition studies, NCI-H292 cells were
pretreated with rebamipide (10, 30 mg/ml; gener-
ously provided by Otsuka Pharma, Korea), with the
EGFR tyrosine kinase inhibitor, AG1478 (10 mM;
Calbiochem, San Diego, CA, USA), or with TNFa
monoclonal antibody, infliximab (3, 6, 9, 12 mg/ml)
30min before they were incubated in cigarette
smoke solution. Infliximab was purchased from a
pharmaceutic supplier (Schering Korea Ltd., Seoul,
Korea).
Immunoblotting for activated EGFR: Cells were
serum starved for 24 h and then stimulated with
cigarette smoke solution for 15min. After stimula-
tion, cells were lysed with lysis buffer (20mM
sodium phosphate, pH 7.8, 150mM NaCl, 5mM
EDTA, 50mM HEPES, 1% Triton X-100, 50mM NaF,
1mM sodium orthovanadate, 5mM phenylmethyl-
sulfonyl fluoride, and 10 mg/ml each of leupeptin
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remove insoluble materials, cell lysates were
centrifuged at 14,000 rpm for 5min at 4 1C. Aliquots
of supernatants containing equal amounts of
protein were suspended in SDS sample buffer and
boiled for 5min. Proteins were separated by SDS-
PAGE in 8% acrylamide gels. The resulting gels were
equilibrated in transfer buffer: 25mM Tris–HCl,
192mM glycine, and 20% (vol/vol) methanol, pH
8.3, and proteins were transferred electrophoreti-
cally to nitrocellulose membranes. The membranes
were incubated with 5% fat-free skimmed milk in
phosphate-buffered saline (PBS) containing 0.05%
Tween 20 for 1 h and then incubated with anti-
phospho-specific EGFR monoclonal antibody (EGFR-
p; 1:1000; 1 mg/ml; Calbiochem, San Diego, CA,
USA) and anti-EGFR (Ab-2) monoclonal antibody
(EGFR; 1:1000; 100 mg/ml; Oncogene, La Jolla, CA,
USA) overnight. Bound antibodies were visualized
according to a standard protocol for the avidin–
biotin–alkaline phosphatase complex method (ABC
kit; Vector Laboratories, Burlingame, CA, USA).
Measurement of TNFa: NCI-H292 cells were
incubated with various concentrations of cigarette
smoke solution or were treated in culture medium
with or without various concentrations of rebami-
pide (10 mg/ml or 30 mg/ml). TNFa levels were
determined in the supernatants harvested after 6,
12, 24 and 48 h by ELISA (Sigma, St Louis, MO, USA).
Immunoassay of MUC5AC protein: NCI-H292 cells
were incubated with various concentrations of
cigarette smoke solution or were treated in culture
medium with rebamipide, AG1478 or TNFa mono-
clonal antibody (infliximab). MUC5AC protein levels
were measured as described previously.7 In brief,
cell lysates were prepared with PBS at multiple
dilutions, and 50 ml of each sample was then
incubated with bicarbonate–carbonate buffer
(50 ml) at 40 1C in a 96-well plate (Maxisorp Nunc;
Fisher Scientific, Santa Clara, CA, USA) until dry.
The plates were then rewashed three times with
PBS and blocked with 2% bovine serum albumin,
fraction V (Sigma, St Louis, MO, USA) for 1 h at room
temperature. The plates were then rewashed three
times with PBS and incubated with 50 ml of MUC5AC
monoclonal antibodies (clone 45 M1, 1:100; Neo-
Markers, Fremont, CA, USA) diluted with PBS
containing 0.05% Tween 20. After 1 h, the wells
were washed three times with PBS, and 100 ml of
horseradish peroxidase-goat anti-mouse IgG con-
jugate (1:10,000) was dispensed into each well.
After a further 1 h, the plates were washed three
times with PBS. Color reaction was developed using
3,30,5,50-tetramethylbenzidine peroxidase solution
(Kirkegaard and Perry Laboratories, Gaithersburg,
MD, USA) and stopped with 2N H2SO4. Absorbancewas read at 450 nm. Each experiment was repeated
at least five times. Mucin of the submandibular
gland was used as a positive ELISA control and naı¨ve
medium (RPMI+10% FBS, never exposed to cells)
was used a negative control. The interassay
variation was less than 5%.In vivo studies
Induction of goblet cell metaplasia by cigarette
smoke exposure: Male Sprague-Dawley rats weigh-
ing 150 g were used for the study. Animals were
housed in a temperature- and humidity-controlled
room and had free access to water and standard
laboratory food. Animals were assigned at random
to the nonsmoking control group or to the smoke-
exposed control or treatment groups. Five animals
were studied in each group. Rats in the smoking
groups were exposed to five cigarettes a day for 5
days (code 2R4F, produced by the Tobacco and
Health Research Institute, University of Kentucky).
On each day of exposure, animals were placed
individually inside a Plexiglas cabinet (40
90 100mm). Cigarette smoke was delivered into
the cabinet by air inflow at a rate of 1.7ml/s
through a burning cigarette in the chamber. The
combustion time of the cigarette was 3min. A
ventilator inside the cabinet ensured rapid and
equal distribution of smoke. Fresh air was delivered
into the cabinet to remove the smoke. Animals
were exposed to cigarettes at intervals of 30min.
During exposure, animals, including control ani-
mals, did not receive food or water, but were
allowed free access to both after exposure.
Inhibition of cigarette smoke-induced goblet cell
metaplasia by rebamipide: To evaluate the effect
of rebamipide on goblet cell metaplasia and mucus
production, animals were treated once daily with
vehicle (distilled water) or with rebamipide in
vehicle at doses of 300 or 1000mg/kg orally 1 day
before exposure to cigarette smoke. Animals were
euthanized 10 days after exposure to cigarette
smoke.
Bronchoalveolar lavage (BAL) cell and cytokine
analysis: Animals were euthanized 1 day after the
last exposure to cigarette smoke for BAL. BAL fluid
was used for cytospin preparations. The slides were
fixed and stained with Diff-Quick (Baxter Health-
care, McGaw Park, IL, USA), and differential cell
counts were obtained by using light microscopic
evaluation of 300 cells/slide. Total BAL cell counts
were performed with a hemocytometer. After
removing cells from BAL fluid by centrifugation,
100-ml aliquots were analyzed for the presence of
TNFa by ELISA, using commercially available kits by
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Figure 1 Tyrosine phosphorylation of EGFR induced by
cigarette smoke was inhibited by AG1478 and rebami-
pide. NCI-H292 cells were incubated under the conditions
shown for 15min and lysed. Proteins were separated by
SDS-PAGE in 8% acrylamide gels and blotted with anti-
phospho-specific EGFR monoclonal antibody and anti-
EGFR (Ab-2) monoclonal antibody. Cigarette smoke
increased EGFR-specific tyrosine phosphorylation in NCI-
H292 cells. The effect was inhibited by AG1478 and
rebamipide (bottom, which showed even loading of total
protein in each lane).
S.Y. Lee et al.506following the manufacturer’s instructions (Gen-
zyme, Cambridge, MA, USA).
Tissue preparation: Animals were euthanized
with a lethal dose of pentobarbital sodium
(200mg/kg, intraperitoneal) 5 days after the
session of cigarette smoke, and the systemic
circulation was perfused with 1% paraformaldehyde
in diethylpyrocarbonate (Sigma, St Louis, MO, USA)-
treated PBS via the left ventricle. For paraffin
sections, tissues were placed in 4% paraformalde-
hyde overnight, dehydrated with ethanol, and
embedded in paraffin. The embedded tissues were
cut as cross sections 4 mm thick and placed on glass
slides.
Quantification of goblet cell metaplasia: In all
studies, the carina was examined to obtain con-
sistent sampling. We measured Alcian blue (AB)–
periodic acid-Schiff (PAS)-positive areas and total
epithelial area, and we expressed the results as the
percentages of AB–PAS stained areas to total
epithelial area. Stained slides were examined
under a light microscope (Olympus BX51, Tokyo,
Japan) connected to a video camera (Olympus DP
50, Tokyo, Japan) and images were captured using
software (Viewfinder Lite v 1.0, Pixera Co, Los
gatos, CA, USA). Airway epithelium images were
recorded in six consecutive high-power fields at
 400. Images were analyzed using the SigmaScan
Pro program (SPSS INC, Chicago, IL, USA).Statistics
All data are expressed as means7standard error of
mean (SE). One-way analysis of variance (ANOVA)
was used to determine statistically significant
differences between groups. Scheffe´’s F-test was
used to correct for multiple comparisons when
statistical significances were identified in the
ANOVA. Po0:05 for the null hypothesis was
accepted as indicating a statistically significant
difference.Results
In vitro studies in NCI-H292 cells
Cigarette smoke induced EGFR tyrosine phosphor-
ylation: Because the activation of EGFR leads to
MUC5AC synthesis,7 we examined the effect of
cigarette smoke solution on activation of the EGFR
tyrosine kinase. Immunoblot analysis of cell lysates
identified that cigarette smoke solution induced
EGFR-specific tyrosine phosphorylation. This effectwas inhibited by pretreating NCI-H292 cells with
AG1478 or with rebamipide. EGFR expression was
not significantly different for the different lysates,
thus indicating equal protein loading (Fig. 1).Rebamipide inhibited cigarette smoke-
induced TNFa production by NCI-H292 cells
TNFa can induce EGFR expression, which results in
MUC5AC production.7 Therefore, we measured TNFa
levels in cigarette smoke-stimulated NCI-H292 cells
at 6, 12, 24, and 48h. Peak TNFa levels were
observed at 24h (not shown). NCI-H292 cells were
treated with various doses of cigarette smoke and
TNFa levels were measured in the culture super-
natants of the cells. Cigarette smoke solution
induced dose-dependently TNFa production from
NCI-H292 cells (not shown), whereas TNFa production
did not increase in cells pretreated with rebamipide.
Thus, rebamipide had an inhibitory effect on TNFa
production in cigarette smoke-stimulated NCI-H292
cells, dose-dependently (Fig. 2).
Rebamipide prevents MUC5AC production in NCI-
H292 cells: NCI-H292 cells were treated with
various doses of cigarette smoke. Cigarette smoke
solution caused increase MUC5AC protein synthesis
dose-dependently, and this effect was prevented by
pretreatment of the cells with rebamipide, dose-
dependently (Fig. 3). Increased MUC5AC protein
synthesis was near completely inhibited by AG1478.
Also we examined whether cigarette smoke solu-
tion induced MUC5AC protein synthesis was influ-
enced by TNFa. Cigarette smoke solution induced
MUC5AC protein synthesis was inhibited by TNFa
monoclonal antibody (infliximab), dose-depen-
dently (Fig. 4).
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Figure 2 Cigarette smoke-induced TNFa secretion was
inhibited by rebamipide dose-dependently in NCI-H292
cells (n ¼ 5, Po0:05, Po0:01 compared with control,
yPo0:05, zPo0:01 compared with five puffs of cigarette
smoke solution alone, yPo0:05 compared with rebami-
pide 10 mg/ml).
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Figure 3 Effects of cigarette smoke solution and reba-
mipide on MUC5AC production in NCI-H292 cells. Cigar-
ette smoke solution increased MUC5AC production dose-
dependently (n ¼ 5, Po0:05, Po0:01 compared with
control, yPo0:05, zPo0:01 compared with five puffs of
cigarette smoke solution alone, yPo0:05 compared with
rebamipide 10 mg/ml), and this increase was inhibited
dose-dependently by rebamipide. MUC5AC protein levels
were measured by ELISA.
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Figure 4 Effects of TNFa inhibitor (infliximab) on
smoking solution induced MUC5AC production in NCI-
H292 cells. Cigarette smoke solution induced MUC5AC
protein synthesis was inhibited by TNFa monoclonal
antibody (infliximab), dose-dependently. (n ¼ 5,
Po0:05, Po0:01 compared with five puffs of cigarette
smoke solution alone). MUC5AC protein levels were
measured by ELISA.
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Cigarette smoke-stimulated rats induces airway
inflammation and TNFa production: Because acti-
vated neutrophils have been implicated in mucinproduction in airway epithelial cells and because
neutrophils are the predominant leukocytes re-
cruited into airways by cigarette smoke, we
examined by using BAL fluid analysis. The BAL
fluids of control rats contained few inflammatory
cells, but the stimulation of rat airways with
cigarette smoke caused inflammatory cell recruit-
ment, predominantly neutrophils and macro-
phages. Moreover, pretreatment with rebamipide
inhibited the recruitment of neutrophils in BAL
fluids (Fig. 5A).
TNFa has been shown to induce EGFR expression
in airway epithelium, and thus, we examined the
effect of cigarette smoke on TNFa secretion in BAL
fluids. In control rats, TNFa secretion was minimal.
However, stimulation with cigarette smoke in-
creased TNFa secretion in BAL fluids of cigarette
smoking group (Fig. 5B), and rebamipide inhibited
this cigarette smoke-induced TNFa secretion.
Cigarette smoke increases goblet cell production
in rat airways: In control animals, the airway
epithelium was stained sparsely by AB/PAS. The
inhalation of cigarette smoke (five cigarettes/day
for 5 days) resulted in a marked increased in
AB–PAS stained areas (Fig. 6A). Moreover, pretreat-
ment of rats with rebamipide inhibited goblet cell
metaplasia dose-dependently (Fig. 6B). These
results indicate that rebamipide prevents cigarette
smoke-induced mucin production in rat airways.
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Figure 5 Effects of cigarette smoke on leukocyte recruitment (A) and on TNFa secretion (B) in BAL fluids. Cigarette
smoke increased neutrophil recruitment. Pretreatment with rebamipide (300mg/kg) inhibited cigarette smoke-induced
leukocyte recruitment (n ¼ 5, Po0:01 compared with control, yPo0:05 compared with cigarette smoke alone). ELISA
analysis showed that cigarette smoke significantly increased in TNFa (n ¼ 5; Po0:01 compared with control).
Rebamipide inhibited cigarette smoke-induced TNFa secretion (yPo0:05 compared with cigarette smoke alone).
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In the present study, we investigated whether
rebamipide prevents mucus production in the
cigarette smoke-stimulated airway epithelium,
because rebamipide has an inhibitory effect on
TNFa production and recruitment of neutrophils on
airway. Our results show that exposure of the
airway epithelium to cigarette smoke induces the
release of TNFa and the recruitment of neutrophils,
which activate EGFR, and MUC5AC mucin synthesis.
Pretreatment with rebamipide prevents this re-
lease of TNFa from airway epithelium and the
recruitment of neutrophils into the airway epithe-
lium, indicating that rebamipide prevents cigarette
smoke-induced MUC5AC mucin production.
The main risk factor of COPD is cigarette
smoking, which is closely associated with mucus
hypersecretion. Exposure to cigarette smoke acti-
vates an inflammatory cascade in the airway
epithelium, which results in the production of a
number of potent cytokines and chemokines,damage to the lung epithelium, increased mucus
secretion, and the recruitment of macrophages and
neutrophils into the airway epithelium.22 Multiple
mechanisms have been suggested to be responsible
for cigarette smoke-induced mucus hypersecretion.
One of the reported mechanisms involves EGFR
upregulation, and EGFR tyrosine kinase activation
by its ligand or its transactivation by oxidative
stress, thus causing mucin MUC5AC expression at
both the mRNA and protein levels in airway
epithelial cells in vitro, or mucin MU5AC production
and goblet cell metaplasia in vivo.11 EGFR activa-
tion may involve two pathways, namely, ligand-
dependent and ligand-independent EGFR tyrosine
phosphorylation.23 In ligand-dependent EGFR tyr-
osine phosphorylation, EGFR ligands (EGF or TGFa)
bind to EGF receptors in the extracellular domain
and activate them while, in ligand-independent
EGFR tyrosine phosphorylation, EGFR tyrosine
phosphorylation occurs in the absence of exogenous
EGFR ligands. According to Shao et al., metallo-
protease TNFa-converting enzyme (TACE) is
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Figure 6 Photomicrographs of rat airway epithelium
stained with AB/PAS(A) and the % area stained by AB/
PAS in airway epithelium (B). Cigarette smoke increased
AB/PAS staining. Pretreatment with rebamipide (300 and
1000mg/kg day orally) prevented the cigarette smoke-
induced effects. Results are representative of those for
five rats (Po0:05, Po0:01 compared with control,
yPo0:05, zPo0:01 compared with five puffs of cigarette
smoke alone). Photomicrographs are shown at  20
magnification; insets,  40 magnification.
Inhibitory effects of rebamipide on smoking induced mucin production 509activated by cigarette smoke, resulting in cleaving
EGFR proligand (TGFa which is constitutively
expressed in airway epithelial cells), leading to
EGFR phosphorylation and mucin induction.24,34
Ligand-independent EGFR phosphorylation is re-
ported in response to oxidative stress that can be
produced by cigarette smoke and by activated
neutrophils.10,11,25 Cigarette smoke inhalation in-
creased TNFa, oxygen-free radical production and
neutrophil recruitment in airways. Ultimately,
cigarette smoke inhalation activated EGFR and
increased mucin MUC5AC production by proinflam-
matory cytokines and neutrophils.
TNFa is a potent proinflammatory cytokine and is
elevated in the sputum of patients with COPD.26
Although the mechanisms by which TNFa causes
cytokine stimulation and apoptosis have been wellstudied, comparatively little is known about the
mechanisms by which TNF stimulates EGFR. In
recent years, evidence has emerged that implicates
TNFa in the regulation of mucus secretion. In
particular, TNFa has been shown to induce mucus
hypersecretion in human airway epithelial cells
in culture.27,28 Moreover, the mucin produced by
TNFa was found to be mediated by MUC5AC or
MUC2 gene expression.29,30 The transactivation of
EGFR by TNFa has been previously described.31–33
Chen et al.32 demonstrated the role of EGFR
signaling in TNF-induced cell proliferation using a
selective pharmacological inhibitor of EGFR kinase
activity.
Rebamipide is an anti-ulcer drug, and has been
reported to prevent various acute experimental
gastric lesions and to accelerate chronic gastric
ulcer healing.12,35 In particular, rebamipide has
known cytoprotective effects in humans and ani-
mals.36 For example, rebamipide was found to
enhance gastric mucosal defense by increasing the
COX-2-dependent production of PGs in gastric
mucosa.37 In addition, rebamipide increased mucin
release in an eye model of inflammation (the N-
acetylcysteine model). However, it is not known
whether changes in mucus expression in the N-
acetylcysteine model accurately reflect what oc-
curs during normal aqueous tearing or during
aqueous tear deficiency.38 Recent studies have also
reported that rebamipide has a beneficial effect on
inflammatory diseases; rebamipide is known as
inhibitor of proinflammatory cytokines, neutrophil
activation, and oxidative stress.20,39,40 However,
the mechanisms underlying these effects are not
well understood.
In our study, cigarette smoke was found to induce
significant TNFa release and MUC5AC protein
synthesis from NCI-H292 cells (Figs. 2 and 3), and
rebamipide was found to inhibit TNFa release dose-
dependently, and to inhibit cigarette smoke-in-
duced MUC5AC production. And this increased
MUC5AC protein synthesis was inhibited by TNFa
monoclonal antibody (Fig. 4). Together these
findings indicate that TNFa is a regulator of
MUC5AC protein synthesis.
In vivo studies, little TNFa protein expression was
observed in control animals, but animals exposed to
cigarette smoke showed TNFa and neutrophils
upregulation, which could have resulted in goblet
cell metaplasia (Figs. 5 and 6). Thus, pretreatment
with rebamipide was found to prevent TNFa release
and neutrophil recruitment in cigarette smoke-
stimulated airways, and to inhibit goblet cell
metaplasia. These results imply that rebamipide
treatment could reduce mucin production in cigar-
ette smoking model.
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S.Y. Lee et al.510In conclusion, we found that the exposure of the
airway epithelium to cigarette smoke induces
neutrophil recruitment, TNFa release, and upregu-
lates EGFR expression, causing MUC5AC mucin
synthesis. Rebamipide was found to prevent TNFa
release, neutrophil recruitment into the airways,
and MUC5AC mucin synthesis in cigarette smoke-
stimulated airway epithelium. These results sug-
gest that rebamipide may be used to treat mucus
hypersecretion in cigarette smokers.References
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